Skip to main content
. 2022 Apr 19;3(3):269–278. doi: 10.1016/j.hroo.2022.04.003

Table 1.

Baseline characteristics and demographics between the two groups with long-standing persistent AF

Group 1 (n = 40) Group 2 (n = 80) P value
Age (y) 57.5 ± 9.3 56.5 ± 8.9 .590
BMI (kg/m2) 25.2 ± 6.5 25.9 ± 2.5 .489
Male 34 (85.0) 73 (91.3) .355
Diabetes mellitus 5 (12.5) 7 (8.8) .531
CHF 4 (10.0) 10 (12.5) .772
Hypertension 15 (37.5) 38 (47.5) .334
CAD 3 (7.5) 7 (8.8) 1
Ischemic stroke 3 (7.5) 12 (15.0) .380
CHA₂DS₂-VASc score 1.26 ± 1.2 1.06 ± 1.0 .426
AF duration (mo) 39.7 ± 27 40.9 ± 26 .758
LDL (mg/dL) 107 ± 30 106 ± 18 .898
LA diameter (mm) 47.2 ± 5.1 45.9 ± 4.3 .221
Procedural time (min) 219 ± 70 150 ± 49 <.001
Patients with PV CARTOFINDER-identified activity 29 (72.5)
Termination of AF during PV isolation 1 (2.5) 3 (3.8) .719
Patients with non-PV trigger or CARTOFINDER-identified activity 38 (95.0) 15 (18.8) <.001
Termination of AF during non-PV atrial ablation 2 (5.0)
Acute reconnection of PV 2 (5.0) 4 (5.0) 1
Additional ablation area of CARTOFINDER-identified activity around RPV antrum (cm2) 0.53 ± 0.8
Additional ablation area of CARTOFINDER-identified activity around LPV antrum (cm2) 0.79 ± 1.4
Complications 1 (2.5) 2 (2.5) 1
 Tamponade 0 (0) 0 (0)
 Pseudoaneurysm 1 (2.5) 2 (2.5)
 Phrenic nerve injury 0 (0) 0 (0)
Amiodarone, before ablation 22 (55.0) 46 (51.7)
Amiodarone, after ablation 14 (35.0) 36 (45.0)
No. of AADs during follow-up 1.1 ± 0.8 1.2 ± 0.6 .517
Recurrence of AF 12 (30.0) 56 (70.0) <.001
Recurrence of atrial flutter 6 (15.0) 20 (25.0) .247
Recurrence of atrial tachycardia 0 (0) 2 (2.5) .552

Values are given as mean ± SD or n (%) unless otherwise indicated.

AAD = antiarrhythmic drug; AF = atrial fibrillation; BMI = body mass index; CAD = coronary artery disease; CHF = congestive heart failure; LA = left atrium; LDL = low-density lipoprotein; LPV = left pulmonary vein; PV = pulmonary vein; RPV = right pulmonary vein.